Al-Rodhan et al., “Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem,” Brain Res., 1991, 557:227-235. |
Bissette et al., “Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin,” Nature, 1976, 262:607-609. |
Carraway and Leeman, “The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami,” J. Biol. Chem., 1973, 248:6854-6861. |
Clineschmidt and McGuffin, “Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli,” Eur. J. Pharmacol., 1977, 46:395-396. |
Cusack et al., “Pharmacological studies on novel neurotensin mimetics: discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist,” Mol. Pharmacol., 1993, 44:1036-1040. |
Cusack et al., “Pharmacological and biochemical profiles of unique neurotensin 8-13 analogs exhibiting species selectivity, stereoselectivity, and superagonism,” J. Biol. Chem, 1995, 270:18359-18366. |
Fauq et al., “Synthesis of (2S)-2-amino-3-(1H-4-indolyl) propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides,” Tetrahedron: Asymmetry, 1998, 9:4127-4134. |
Huang and Hanson, “Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems,” Eur. J. Pharmacol., 1997, 332:15-21. |
Jolicoeur et al., “Differential neurobehavioral effects of neurotensin and structural analogues,” Peptides, 1981, 2:171-175. |
Kitabgi et al. “Neurotensin binding to extraneural and neural receptors: comparison with biological activity and structure-activity relationships,” Mol. Pharmacol., 1980, 18:11-19. |
Lambert et al., “Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system,” Ann. N.Y. Acad. Sci., 1995, 757:377-389. |
Li et al., “Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study,” J. Neural. Transm., 1995, 102:125-137. |
Morbeck et al., “Analysis of hormone-receptor interaction sites using synthetic peptides: Receptor binding regions of the alpha-subunit of human choriogonadotropin,” Methods: A Companion to Methods in Enzymology, 1993, 5:191-200, Academic Press Inc., New York. |
Radke et al., “Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions,” Proc. Natl. Acad. Sci. USA, 1998, 95:11462-11464. |
Sarhan et al., “Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist,” Peptides, 1997, 18(8):1223-1227. |
Snijders et al., “Neurotensin induces catalepsy in mice,” Neuropharmacology, 1982, 21:465-468. |
Troxler von Franz, “Praparative verwendung von mannich-basen von hydroxy-indolen als alkylierungsmittel,” Helvetica Chimica Acta, 1968, Volumen 51, Fasciculus 6, pp. 1214-1224. |
Tyler et al., “In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier,” Neuropharmacology, 1999, 38:1027-1034. |
Vincent Jean-Pierre et al., “Neurotensin and neurotensin receptors,” TIPS, 1999, 20:302-309. |